Preview Mode Links will not work in preview mode
Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show offers a glimpse into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the evolving dynamics in the medical and healthcare landscape. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations often focus on how technology is empowering providers, care facilities, pharmaceutical companies, and payers to improve patient outcomes and reduce friction across the healthcare landscape.  Popular Topics Include: Virtual and digital health Use of AI, ML, and robots for clinical and administrative purposes  Value-based healthcare  Precision and stratified medicine Next-generation immuno, cell, and gene therapies Vaccines for infectious diseases and oncology Biomarkers and diagnostics Rare diseases MedTech and medical devices Clinical trials  Population health Chronic conditions l Clinician and staff burnout Smart hospitals The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.

Feb 5, 2024

Chris Paradise, VP of Research and Development at Rion, is taking an acellular approach to developing next-generation regenerative medicines to treat degenerative diseases. The proprietary Rion system PEP, purified exosome product, uses extracellular vesicles or exosomes isolated from human blood platelets to send regenerative messages to cells to stimulate faster healing. This regenerative therapeutic allows for the administration in various forms, such as nebulization for pulmonary conditions and topical application for wounds.

Chris explains, "What our focus has shifted towards at Rion is now an acellular approach, so it doesn't involve the use of cells or other components that have been proposed in the past. But we're focusing on extracellular vesicles or exosomes, and we can discuss those in more detail in a minute. But the point of emphasis is that it overcomes many of the limitations the field has previously faced. We're excited to offer reproducible, consistent, and, most importantly, accessible and affordable regenerative therapeutic with a significant impact."

"If you think about how two cells communicate with one another, one of the ways they do this is to send messages in little packages between one another, known as extracellular vesicles. It's the fundamental way that cells and tissues more broadly communicate with each other, send signals to one another, and respond to their environment. And so what you find within these vesicles is essentially what one cell is trying to say to another. And they're designed such that they're incredibly stable and designed to do exactly that, which is deliver messages to cells."

"I'll back up to the source of the material, which is human platelets. Most people are familiar with platelets as a key component of your blood. If we get an injury or a cut, the bleeding tends to stop relatively quickly. That's because platelets respond to that injury site and form a clot, which stops the bleeding. Much like the conversation about the newfound appreciation for exosomes, I've certainly gained a new appreciation for the impact platelets have, not only on the control of bleeding but, more importantly, the regenerative processes that are jump-started after that to heal the tissues."

#RionTX #RegenerativeMedicine #RegenerativeTherapeutics #Acellular #PlateletDerived #Exosomes 

riontx.com

Download the transcript here

Rion